Sequenta Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
41
- Latest Deal Type
-
M&A
- Investors
-
1
Sequenta General Information
Description
Developer of clinical diagnostics based on a new platform for understanding immune system status. The company develops new approaches for measuring the variable part of the human genome, the immune cell receptor genes.
Contact Information
Website
www.sequenta.comCorporate Office
- 400 East Jamie Court
- Suite 301
- South San Francisco, CA 94080
- United States
Corporate Office
- 400 East Jamie Court
- Suite 301
- South San Francisco, CA 94080
- United States
Sequenta Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 07-Jan-2015 | Completed | Product Development | |||
| 4. Later Stage VC (Series D) | 20-Oct-2014 | Completed | Product Development | |||
| 3. Later Stage VC (Series C) | 02-Jul-2013 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 22-Feb-2012 | $17M | $19.1M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 15-Jul-2009 | $2.1M | $2.1M | Completed | Startup |
Sequenta Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 5,924,623 | $0.000100 | $0.25 | $3.15 | $3.15 | 1x | $3.15 | 21.16% |
| Series A | 1,351,460 | $0.000100 | $0.12 | $1.55 | $1.55 | 1x | $1.55 | 4.83% |
Sequenta Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sequenta Patents
Sequenta Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2015153788-A1 | Determining antigen-specific t-cells and b-cells | Inactive | 01-Apr-2014 | ||
| WO-2015058159-A1 | Predicting patient responsiveness to immune checkpoint inhibitors | Inactive | 18-Oct-2013 | ||
| US-20160186260-A1 | Cancer vaccination with antigen evolution | Inactive | 26-Jul-2013 | ||
| WO-2015013461-A2 | Cancer vaccination with antigen evolution | Inactive | 26-Jul-2013 | ||
| WO-2015013461-A3 | Cancer vaccination with antigen evolution | Inactive | 26-Jul-2013 | C12Q1/6881 |
Sequenta Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sequenta Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Celgene | Corporation | Minority | ||
| Angel (individual) | ||||
| Foresite Capital | Growth/Expansion | Minority | ||
| Illumina | Corporation | Minority | ||
| Index Ventures | Venture Capital | Minority |
Sequenta FAQs
-
When was Sequenta founded?
Sequenta was founded in 2008.
-
Where is Sequenta headquartered?
Sequenta is headquartered in South San Francisco, CA.
-
What is the size of Sequenta?
Sequenta has 41 total employees.
-
What industry is Sequenta in?
Sequenta’s primary industry is Biotechnology.
-
Is Sequenta a private or public company?
Sequenta is a Private company.
-
What is Sequenta’s current revenue?
The current revenue for Sequenta is .
-
How much funding has Sequenta raised over time?
Sequenta has raised $89.1M.
-
Who are Sequenta’s investors?
Celgene, , Foresite Capital, Illumina, and Index Ventures are 5 of 7 investors who have invested in Sequenta.
-
When was Sequenta acquired?
Sequenta was acquired on 07-Jan-2015.
-
Who acquired Sequenta?
Sequenta was acquired by Adaptive Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
